COVID-19 treatment: GlaxoSmithKline Australia Pty Ltd, sotrovimab (XEVUDY)
On 17 August 2021 the TGA granted provisional approval to GlaxoSmithKline Australia Pty Ltd in relation to sotrovimab (XEVUDY).
Published
Last updated
Related content
- TGA provisionally approves GlaxoSmithKline's COVID-19 treatment: sotrovimab (XEVUDY)On 20 August 2021 the TGA granted provisional approval to GlaxoSmithKline Australia Pty Ltd in relation to sotrovimab (XEVUDY).
- COVID-19 treatment: Gilead Sciences Pty Ltd, remdesivir (VEKLURY)On 10 July 2020 the Therapeutic Goods Administration (TGA) granted provisional approval to remdesivir ("Veklury", Gilead Sciences Pty Ltd) as the first treatment option for COVID-19
- TGA grants provisional determination to Glaxo SmithKline Australia Pty Ltd for COVID-19 monoclonal antibody treatment - SOTROVIMABThe granting of a provisional determination means that the TGA has made a decision that GSK is now eligible to apply for provisional registration for the treatment in the Australian Register of Therapeutic Goods.